Prostate cancer

Medicina clínica
Joan Moroteen nombre del grupo multidisciplinario para el estudio y tratamiento del cáncer de próstata Vall d’Hebron

Abstract

The Vall d'Hebron multidisciplinary prostate cancer (PC) team reviews recent advances in the management of this neoplasm. Screening studies with long follow-up show a reduction in mortality, whereas active surveillance is emerging as a therapeutic approach of non-aggressive cancers. New markers increase the specificity of PSA and also allow targeting suspected aggressive cancers. Multiparametric magnetic resonance (mMRI) has emerged as the most effective method in the selection of patients for biopsy and also for local tumor staging. The paradigm of random prostatic biopsy is changing through the fusion techniques that allow guiding ultrasonography-driven biopsy of suspicious areas detected in mMRI. Radical prostatectomy (RP) and radiotherapy (RT) are curative treatments of localized PC and both have experienced significant technological improvements. RP is highly effective and the incorporation of robotic surgery is reducing morbidity. Modern RT allows the possibility of high tumor dose with minimal adjacent dose reducing its toxicity. Androgen deprivation therapy with LHRH analogues remains the treatment of choice for advanced PC, but should be limited to this indication. The loss of bone mass and adverse metabolic effects in...Continue Reading

References

Jun 6, 2006·The Lancet Oncology·Edward M MessingUNKNOWN Eastern Cooperative Oncology Group study EST 3886
Sep 4, 2007·International Journal of Radiation Oncology, Biology, Physics·Deborah A KubanAlan Pollack
Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard I ScherUNKNOWN Prostate Cancer Clinical Trials Working Group
Mar 4, 2008·International Journal of Radiation Oncology, Biology, Physics·Michael J ZelefskyHoward I Amols
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laurence KlotzAndrew Loblaw
Apr 22, 2010·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Caroline J SavageAndrew J Vickers
Jul 8, 2010·International Journal of Radiation Oncology, Biology, Physics·Al V TairaKent E Wallner
May 27, 2011·The New England Journal of Medicine·Johann S de BonoUNKNOWN COU-AA-301 Investigators
Sep 3, 2011·BJU International·Hein van PoppelMichael Marberger
Dec 22, 2011·Cancer Imaging : the Official Publication of the International Cancer Imaging Society·A R Padhani
Jan 25, 2012·International Journal of Radiation Oncology, Biology, Physics·Xinglei ShenTimothy N Showalter
Feb 11, 2012·European Radiology·Jelle O BarentszUNKNOWN European Society of Urogenital Radiology
Aug 17, 2012·The New England Journal of Medicine·Howard I ScherUNKNOWN AFFIRM Investigators
Nov 20, 2012·European Urology·Meelan BulMonique J Roobol
Jan 16, 2013·Current Treatment Options in Oncology·Laurence Klotz
Jul 19, 2013·The New England Journal of Medicine·C ParkerUNKNOWN ALSYMPCA Investigators
Sep 26, 2013·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Christopher R KingAlan Katz
Oct 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan PollackMark K Buyyounouski
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
May 21, 2014·Nature Reviews. Clinical Oncology·Linda M JohnsonPeter L Choyke
Oct 30, 2014·The New England Journal of Medicine·Tomasz M Beer, Bertrand Tombal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.